PC30246J Amendment



Certificate of Mailing (37 C.F.R. §1.8): I hereby certify that this correspondence is being deposited with the United States Postal Service First Class Mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 29th day of March 2006.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

JOHAN WILHELM STJERNSCHANTZ

Serial No.: 10/723,140

Filed: November 25, 2003

For: PROSTAGLANDIN DERIVATIVES FOR

THE TREATMENT OF GLAUCOMA OR

OCULAR HYPERTENSION

Group Art Unit: 1626

Examiner: Joseph R. Kosack

Confirmation No.: 9449

Mail Stop: Amendment **Commissioner For Patents** P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

1. Amendment 6 pages;

2. Return Postcard 1 postcard; and

Total Fee Due 3.

Deposit Account.

Respectfully submitted,

Date: March 29, 2001

Attorney For Applicants Registration No. 43,049

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121 Phone: (858) 622-3119

Fax: (858) 678-8233

PC30246J Appln. No. 10/723,140



Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 29th

day of March 2006.

Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

JOHAN WILHELM STJERNSCHANTZ

Application No.: 10/723,140

Filed: November 25, 2003

For: PROSTAGLANDIN DERIVATIVES FOR

THE TREATMENT OF GLAUCOMA OR

OCULAR HYPERTENSION

Confirmation No.: 9449

Group Art Unit: 1626

Examiner: Joseph R. Kosack

AMENDMENT

Mail Stop: Amendment Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sirs:

In response to the Office Action dated December 29, 2005, entry of the following remarks is respectfully requested.

	Amendments to the Specification begin on page _ of this paper;
\boxtimes	Amendments to the Claims are reflected in the Listing of the Claims which begin on page 2 of this paper;
	Amendments to the Drawings begin on page _ of this paper; and
\boxtimes	Remarks begin on page 4 of this paper.